News | January 07, 2015

Volcano Announces 1,000th System Activated With iFR Modality

Hybrid method avoids need for hyperemic agents that induce stress on the heart


January 7, 2015 — Volcano Corp. announced that more than 1,000 systems have been activated with its instant wave-Free Ratio (iFR) Modality software, featuring a simplified workflow and reduced need for hyperemic agents.

The iFR Modality is a physiologic measurement performed using the same pressure wires and equipment utilized in cardiac catheterization labs for fractional flow reserve (FFR) but avoids injection of hyperemic agents into the patient that induce stress to the heart. This allows for a meaningful, lesion-specific assessment in seconds by amplifying the resting pressure waveform. The iFR Modality is used most efficiently with Volcano's Verrata Pressure Guide Wire, which is designed for simple disconnection and reattachment during a procedure and facilitates multiple quick measurements without the need for hyperemic agents.

The iFR Modality and other physiologic guidance tools including FFR and coronary flow reserve (CFR) are currently being studied in numerous prospective clinical trials as part of the DEFINE family of studies. These studies are designed to explore patient outcomes in a broad array of clinical presentations in more than 5,000 patients worldwide.  The performance of the iFR Modality has been tested in approximately 800 patients as part of ADVISE II (Adenosine Vasodilator Independent Stenosis Evaluation), the first prospective, real-world registry comparing iFR and FFR. The iFR Hybrid Approach Analysis performed in the ADVISE II study demonstrated a statistically high correlation (sensitivity 90.7 percent for FFR less than or equal to 0.80, specificity 96.2 percent for FFR greater than 0.80). The hybrid method would have avoided the need to use a hyperemic agent in 65.1 percent of this patient population. Patients in ADVISE II were recruited from more than 40 centers in the United States and Europe, and all procedures were performed with operators blinded to the iFR values which were calculated offline at an independent core laboratory in Rotterdam, the Netherlands. 

"We chose to evaluate the hyperemic savings in our own subset of patients and have been very pleased with iFR," commented Vincent J. Pompili, M.D., FACC, director, Interventional Cardiovascular Medicine and Cardiac Catheterization Laboratories at The Ross Heart Hospital at The Ohio State University Wexner Medical Center. "In our subset of patients thus far, we've seen more than a 60-percent reduction in the need for hyperemic agents using the iFR Hybrid Approach, which is consistent with the ADVISE II study. Our patients appreciate not having to receive a hyperemic agent but still receive the benefits of intracoronary physiologic measurements. So far I have been impressed with the ease of use, and repeatability of the software."

For more information: www.volcanocorp.com

Related Content

News | Cath Lab

October 6, 2021 — Boston Scientific Corp. announced it entered into a definitive agreement to acquire Baylis Medical ...

Home October 06, 2021
Home
News | Cath Lab

September 21, 2021 — Medtronic is recalling its Pipeline Flex Embolization Device and Pipeline Flex Embolization Device ...

Home September 21, 2021
Home
Feature | Cath Lab | By Aaron Detate and Lars Thording

In the electrophysiology (EP) lab, hundreds of thousands of used devices are sent to reprocessors every year to get ...

Home September 14, 2021
Home
News | Cath Lab

July 22, 2021 — Medis Medical Imaging is partnering with CORRIB Core Lab and Sinomed in randomized clinical trial of ...

Home July 22, 2021
Home
News | Cath Lab

July 13, 2021 — East End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company ...

Home July 14, 2021
Home
Feature | Cath Lab | By Dave Fornell, Editor

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal ...

Home May 14, 2021
Home
News | Cath Lab

May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has ...

Home May 12, 2021
Home
Feature | Cath Lab | By Dave Fornell, Editor

April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from the ...

Home May 06, 2021
Home
Videos | Cath Lab

Ashwin Nathan M.D., a cardiology fellow in the division of Cardiovascular Medicine at the Hospital of the University of ...

Home May 05, 2021
Home
News | Cath Lab

May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for stable ...

Home May 03, 2021
Home
Subscribe Now